Results 11 to 20 of about 22,889 (244)
JAMA Oncology, 2023 Importance Patients with relapsed small cell lung cancer (SCLC), a high replication stress tumor, have poor prognoses and few therapeutic options. A phase 2 study showed antitumor activity with the addition of the ataxia telangiectasia and Rad3-related ...
N. Takahashi +37 more
semanticscholar +2 more sources
Therapeutic uses of topotecan for thoracic malignancies
Oncology Reviews, 2011 Topotecan, a topoisomerase 1 inhibitor (topo1-i), is a semi-synthetic derivative of camptothecan with wellestablished cytotoxic properties. It is licensed for the treatment of relapsed, sensitive small cell lung cancer (SCLC) and for second line ...
Saoirse O. Dolly +4 more
doaj +2 more sources
Triggering of Suicidal Erythrocyte Death by Topotecan [PDF]
Cellular Physiology and Biochemistry, 2015 Background/Aims: The topoisomerase I inhibitor topotecan is used as treatment of various malignancies. The substance is effective by triggering tumor cell apoptosis. In analogy to apoptosis of nucleated cells, erythrocytes may enter eryptosis, a suicidal
Rosi Bissinger +4 more
doaj +2 more sources
Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. [PDF]
PLoS ONE, 2013 PURPOSE: Carboplatin administered systemically or periocularly can result in dramatic and prompt regression of retinoblastoma. However, both routes are rarely curative alone and have undesirable side effects.
Jasmine H Francis +6 more
doaj +2 more sources
HIF inhibitor topotecan has a neuroprotective effect in a murine retinal ischemia-reperfusion model [PDF]
PeerJ, 2019 Purpose The therapeutic approach for retinal ganglion cell (RGC) degeneration has not been fully established. Recently, it has been reported that hypoxia-inducible factor (HIF) may be involved with retinal neurodegeneration.
Hiromitsu Kunimi +4 more
doaj +3 more sources
PLoS ONE, 2019 Leptomeningeal metastasis remains a difficult clinical challenge. Some success has been achieved by direct administration of therapeutics into the cerebrospinal fluid (CSF) circumventing limitations imposed by the blood brain barrier.
Gregory M Shackleford +8 more
doaj +2 more sources
Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report [PDF]
Case Reports in OncologyIntroduction: Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse
Davien Deraedt +3 more
doaj +2 more sources
Frontiers in Oncology, 2019 The purpose of this study was to examine pazopanib/topotecan combination activity vs. pazopanib monotherapy on anaplastic thyroid cancer (ATC) cells.
Teresa Di Desidero +3 more
doaj +2 more sources
Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer
BMC Cancer, 2010 Background To undertake a systematic review of the available data for oral and intravenous topotecan in adults with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first line regimen is not considered appropriate.
Riemsma Rob +4 more
doaj +2 more sources
Frontiers in Cell and Developmental Biology, 2020 While topotecan (TPT) is a first- and second-line chemotherapeutic drug in treating lung cancer, the development of drug resistance in tumors still reserves as a major obstacle to chemotherapeutic success.
Zi-Ning Lei +12 more
doaj +2 more sources